Heart failure & cardiomyopathiesSecondary analysis
On-Treatment Analysis of Torsemide Versus Furosemide for Patients Hospitalized for Heart Failure: A Post-Hoc Analysis of TRANSFORM-HF
- Secondary analysis of the TRANSFORM-HF randomised trial
- post-hoc
- on-treatment analysis
- open-label
- pragmatic
Authors' conclusion
In TRANSFORM-HF, a post-hoc on-treatment analysis did not meaningfully differ from the original trial results.
Study context
- Population
- Patients hospitalized for heart failure (HF) (June 2018–March 2022), excluding those confirmed non-adherent to study diuretic2,570 on-treatment at discharge
- Participants
- 2,859 patients
- Comparison
- Torsemide vs furosemide
- Primary endpoint
- All-cause mortality
- Follow-up
- 12 months
Primary result
As reported in the abstract
Torsemide vs FurosemideHazard ratio (95% CI)P value
on-treatment at discharge: 17.5% vs 17.8%
1.01(0.83–1.22)
P = 0.96on-treatment at 30-day follow-up: 14.5% vs 15.0%
1.02(0.81–1.27)
P = 0.90Further findings
| Outcome | Torsemide | Furosemide | Estimate | P value | |
|---|---|---|---|---|---|
| All-cause mortality or all-cause hospitalization · 12 months · on-treatment at discharge | 58.3% | 61.3% | HR 0.92 (95% CI 0.82–1.03) | ||
| All-cause mortality or all-cause hospitalization · 12 months · on-treatment at 30-day follow-up | 60.9% | 64.4% | HR 0.93 (95% CI 0.82–1.05) | ||
| Total hospitalizations (on-treatment at 30-day follow-up) · 12 months | 677 events | 686 events | rate ratio 0.99 (95% CI 0.86–1.14) | P = 0.87 | |
| 0.512Ratio (log scale) |
Original publication
On-Treatment Analysis of Torsemide Versus Furosemide for Patients Hospitalized for Heart Failure: A Post-Hoc Analysis of TRANSFORM-HF. Eur J Heart Fail. Published 15 May 2024. doi:10.1002/ejhf.3293
Summarised from the published abstract; every number is checked against it